Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Colorcon
Mallinckrodt
AstraZeneca
Dow

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Litigation Details for Plaintiff(s) v. Defendant(s) (D. Del. 2019)

See Plans and Pricing

« Back to Dashboard

Plaintiff(s) v. Defendant(s) (D. Del. 2019)

Docket   Start Trial Date Filed 2008-01-31
Court District Court, D. Delaware Date Terminated
Cause Assigned To
Jury Demand Referred To
Parties DEFENDANT(S); PLAINTIFF(S)
Patents 10,010,507; 10,039,745; 10,058,564; 10,106,548; 10,125,140; 10,143,792; 10,154,987; 10,206,939; 10,307,419; 4,138,475; 4,371,516; 4,377,584; 4,387,089; 4,389,393; 4,535,186; 4,572,909; 4,661,491; 4,681,893; 4,760,071; 4,839,177; 4,851,229; 4,879,303; 4,892,741; 4,939,130; 4,966,768; 5,128,143; 5,178,878; 5,208,225; 5,344,932; 5,422,123; 5,643,602; 5,837,284; 5,846,976; 5,859,021; 5,898,032; 5,908,850; 5,998,427; 6,013,657; 6,024,981; 6,149,940; 6,221,392; 6,254,887; 6,274,171; 6,344,215; 6,403,120; 6,419,958; 6,423,340; 6,455,574; 6,500,814; 6,696,481; 6,794,410; 6,974,590; 7,056,500; 7,229,636; 7,404,489; 7,514,444; 7,566,729; 7,635,707; 7,691,411; 7,713,938; 7,723,390; 7,767,700; 7,816,383; 7,846,961; 7,879,349; 7,888,362; 7,910,610; 8,003,111; 8,003,353; 8,008,309; 8,013,002; 8,084,475; 8,101,659; 8,147,866; 8,318,780; 8,349,840; 8,383,150; 8,420,674; 8,476,284; 8,497,277; 8,551,957; 8,592,462; 8,603,506; 8,609,701; 8,618,109; 8,648,098; 8,697,711; 8,735,403; 8,754,090; 8,754,091; 8,754,109; 8,778,947; 8,796,331; 8,877,938; 8,940,714; 8,952,015; 8,957,079; 9,079,949; 9,089,587; 9,181,257; 9,186,346; 9,233,117; 9,233,118; 9,241,946; 9,296,753; 9,388,134; 9,415,007; 9,655,843; 9,655,857; 9,669,008; 9,725,455; 9,808,442; 9,839,637; 9,889,144; 9,901,539; 9,949,998; 9,957,232; RE36,247
Link to Docket External link to docket
Biologic Drugs cited in Plaintiff(s) v. Defendant(s)

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .

Details for Plaintiff(s) v. Defendant(s) (D. Del. 2019)

Date Filed Document No. Description Snippet Link To Document
2008-07-22 115 COMPLAINT United States Patent Nos. 6,423,340 (“the ’340 patent”) and 5,643,602 (“the ’602 patent”). This Court …22/2008 Page 12 Of 23 [11] Patent Nu`mber: [45] Date of Patent: 5,643,602 Ju]. 1, 1997 [54] ORAL …240,0?8, filed May 9, 1994, now U.S. Pat. No. 5,643,602 and which is a continuation of application Ser…Document 115-2 Filed 07/22/2008 Page 13 Of 23 5,643,602 1 ORAL COMPOSITION FOR THE TREATL[ENT DF INFLAMMATORY…Document 115-2 Filed 07/22/2008 Page 14 Of 23 5,643,602 3 the 20R-epimer of [V]I[], methyl (22RS)~1occ External link to document
2008-07-22 116 COMPLAINT United States Patent Nos. 6,200,604 B 1 ("the '604 patent") and 6,974 , 590 B2 ("the…the '590 patent") under the Patent Laws of the United States, 35 U.S.C. § 100 et seq., including…604 and '590 patents under 28 U.S.C. §§ 2201 and 2202. A copy of the '604 patent is attached as… THE PATENTS IN SUIT 11. On March 13, 2001, the '604 patent, titled "…") the '604 and '590 patents (the "Listed Patents") which cover methods of using External link to document
2018-09-21 1168 prior to the expiration of U.S. Patent No. 9,957,232 (the “’232 patent”). As set forth in its… The ’232 Patent 25. U.S. Patent No. 9,957,232, entitled “… 1. This is an action for patent infringement under the patent laws of the United States, Title…forth in greater detail in the ’232 patent, the claims of the ’232 patent, incorporated by reference herein…the ’232 patent. 31. Apotex had knowledge of the claims of the ’232 patent before External link to document
2008-07-24 117 COMPLAINT Connt II (Infringemcnt of United States Patent No. 4,939,130) 39 Each of the preceding paragraphs l …-2 United States Patent int Jaeggi et td. Filed 07/24/2008 Page 2 of 11 4,939,130 Jul. 3, 1990 [ii…Document 117-2 Filed 07/24/2008 Page 3 Of 11 4,939,130 l SUBS'ITIUTED ALKANED]I’HOSPHON'IC …Document 117-2 Filed 07/24/2008 Page 4 of 11 4,939,130 3 mors is likewise inhibited after peroral administration…Document 117-2 Filed 07/24/2008 Page 7 of 11 4,939,130 9 tricalciurn phosphate or calcium bipltosphate External link to document
2008-07-25 118 COMPLAINT Pat. No. 4.839.177. hereby incorporated by reference herein in its entirety. In that patent. the support… Pat. No. 4,839,177, hereby incorporated by reference herein in its entirety. In that patent, the support…United States Patent Nos. 5,662,933 (“the ‘933 patent”) and 5,958,456 (“the ‘456 patent”). This action…1997, the U.S. Patent and Trademark Office (“PTO”) duly and legally issued the ‘933 patent, entitled “Controlled…of the ‘933 and ‘456 patents, and Endo is an exclusive licensee of these patents in the relevant field External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Merck
Dow
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.